PURPOSE: To give an overview over cell therapeutic approaches to immunosuppression in clinical kidney transplantation. A focus is on myeloid suppressor cell therapy by mitomycin C-induced cells (MICs). METHODS: Literature review with an emphasis on already existing therapies. RESULTS: Several cell therapeutic approaches to immunosuppression and donor-specific unresponsiveness are now being tested in early phase I and phase II trials in clinical kidney transplantation. Cell products such as regulatory T cells or regulatory macrophages, or other myeloid suppressor cell therapies, may either consist of donor-specific, third-party, or autologous cell preparations. Major problems are the identification of the suppressive cell populations and their expansion to have sufficient amount of cells to achieve donor unresponsiveness (e.g., with regulatory T cells). We show a simple and safe way to establish donor unresponsiveness in living-donor kidney transplantation by MIC therapy. A phase I clinical trial is now under way to test the safety and efficacy of this cell therapeutic approach. CONCLUSIONS: Cell therapeutic approaches to immunosuppression after kidney transplantation may revolutionize clinical transplantation in the future.
PURPOSE: To give an overview over cell therapeutic approaches to immunosuppression in clinical kidney transplantation. A focus is on myeloid suppressor cell therapy by mitomycin C-induced cells (MICs). METHODS: Literature review with an emphasis on already existing therapies. RESULTS: Several cell therapeutic approaches to immunosuppression and donor-specific unresponsiveness are now being tested in early phase I and phase II trials in clinical kidney transplantation. Cell products such as regulatory T cells or regulatory macrophages, or other myeloid suppressor cell therapies, may either consist of donor-specific, third-party, or autologous cell preparations. Major problems are the identification of the suppressive cell populations and their expansion to have sufficient amount of cells to achieve donor unresponsiveness (e.g., with regulatory T cells). We show a simple and safe way to establish donor unresponsiveness in living-donor kidney transplantation by MIC therapy. A phase I clinical trial is now under way to test the safety and efficacy of this cell therapeutic approach. CONCLUSIONS: Cell therapeutic approaches to immunosuppression after kidney transplantation may revolutionize clinical transplantation in the future.
Authors: Hans-Peter Marti; Jana Henschkowski; Gunter Laux; Bruno Vogt; Christian Seiler; Gerhard Opelz; Felix J Frey Journal: Transpl Int Date: 2006-01 Impact factor: 3.782
Authors: Tatsuo Kawai; A Benedict Cosimi; Thomas R Spitzer; Nina Tolkoff-Rubin; Manikkam Suthanthiran; Susan L Saidman; Juanita Shaffer; Frederic I Preffer; Ruchuang Ding; Vijay Sharma; Jay A Fishman; Bimalangshu Dey; Dicken S C Ko; Martin Hertl; Nelson B Goes; Waichi Wong; Winfred W Williams; Robert B Colvin; Megan Sykes; David H Sachs Journal: N Engl J Med Date: 2008-01-24 Impact factor: 91.245
Authors: Pervinder Sagoo; Niwa Ali; Garima Garg; Frank O Nestle; Robert I Lechler; Giovanna Lombardi Journal: Sci Transl Med Date: 2011-05-18 Impact factor: 17.956
Authors: Weihong Liu; Amy L Putnam; Zhou Xu-Yu; Gregory L Szot; Michael R Lee; Shirley Zhu; Peter A Gottlieb; Philipp Kapranov; Thomas R Gingeras; Barbara Fazekas de St Groth; Carol Clayberger; David M Soper; Steven F Ziegler; Jeffrey A Bluestone Journal: J Exp Med Date: 2006-07-03 Impact factor: 14.307
Authors: Christian Morath; Anita Schmitt; Florian Kälble; Martin Zeier; Michael Schmitt; Flavius Sandra-Petrescu; Gerhard Opelz; Peter Terness; Matthias Schaier; Christian Kleist Journal: Pediatr Nephrol Date: 2017-02-23 Impact factor: 3.714
Authors: Christian Andreas Radu; Sebastian Fischer; Yannick Diehm; Otto Hetzel; Florian Neubrech; Laura Dittmar; Christian Kleist; Martha Maria Gebhard; Peter Terness; Ulrich Kneser; Jurij Kiefer Journal: Langenbecks Arch Surg Date: 2017-08-19 Impact factor: 3.445